You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
九芝堂(000989.SZ):上半年淨利升11.71%至1.97億元
格隆匯 08-14 17:46

格隆匯 8 月 14日丨九芝堂(000989.SZ)披露2020年半年度報告,實現營業收入18.33億元,同比增長8.55%;歸屬於上市公司股東的淨利潤1.97億元,同比增長11.71%;歸屬於上市公司股東的扣除非經常性損益的淨利潤1.92億元,同比增長24.30%;基本每股收益0.23元。

2020年上半年,新冠肺炎疫情席捲全球,給世界各國、各行業造成了前所未有的衝擊,同時也對醫藥行業的發展帶來了積極的影響。在抗擊疫情過程中,中醫藥發揮了重要的作用,多款中藥被正式列入各級診療方案中,臨牀療效觀察顯示,中醫藥在本次疫情防控應用過程總有效率達到了90%以上。中醫藥在抗擊疫情的顯著作用有利於提升中醫藥在國內的戰略性地位和社會認可度,有利於推進中醫藥的國際化進程。同時,政府“從有病治病,到無病防病”的理念倡導也將引領國民健康消費走向更加成熟的階段,大健康產業將迎來重大發展機遇。另一方面,醫療體制改革持續深化,注射劑一致性評價啟動、國家藥品集中帶量採購常態化、醫療保障制度、藥品管理制度等各項醫藥政策密集出台,醫藥行業仍將處於調整階段,行業競爭進一步加劇,行業集中度持續提高。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account